Protein biomarkers have the potential to transform medicine as they are clinically used to diagnose diseases, stratify patients and follow disease states. Even though a large number of potential biomarkers have been proposed over the past few years, almost none of them have been so far implemented in the clinic. One of the reasons for this limited success is the lack of technologies to validate proposed biomarker candidates in larger patient cohorts. This limitation could be alleviated by the use of antibody-independent validation methods such as Selected Reaction Monitoring (SRM). Similar to measurements based on affinity-reagents, SRM based targeted mass spectrometry also requires the generation of definitive assays for each targeted analyte. Here we present a library of SRM assays for 5568 N-glycosites enabling the multiplexed evaluation of clinically relevant N-glycoproteins as biomarker candidates. We demonstrate that this resource can be utilized to select SRM assay sets for cancer-associated N-glycoproteins for their subsequent multiplexed and consistent quantification in 120 human plasma samples. We show that N-glycoproteins spanning five orders of magnitude in abundance can be quantified and that previously reported abundance differences in various cancer types can be recapitulated. Together, the established N-Glycoprotein SRMAtlas resource (available online at http://www.srmatlas.org/) facilitates parallel, efficient, consistent, and sensitive evaluation of proposed biomarker candidates in large clinical sample cohorts.